Preparation of low molecular weight heparin from a remodeled bovine intestinal heparin

No Thumbnail Available
Authors
Baytas, Sultan N.
Varghese, Sony S.
Jin, Weihua
Yu, Yanlei
He, Peng
Douaisi, Marc
Zhang, Fuming
Brodfuehrer, Paul
Xia, Ke
Dordick, Jonathan S.
Issue Date
2021-02-25
Type
Article
Language
ENG
Keywords
Biology , Chemistry and chemical biology , Chemical and biological engineering , Biomedical engineering
Research Projects
Organizational Units
Journal Issue
Alternative Title
Abstract
Bovine intestinal heparins are structurally distinct from porcine intestinal heparins and exhibit lower specific anticoagulant activity (units/mg). The reduced content of N-sulfo, 3-O-sulfo glucosamine, the central and critical residue in heparin’s antithrombin III binding site, is responsible for bovine intestinal heparin’s reduced activity. Previous studies demonstrate that treatment of bovine intestinal heparin with 3-O-sulfotransferase in the presence of 3′-phosphoadenosine-5′-phosphosulfate afforded remodeled bovine heparin with an enhanced activity reaching the United States Pharmacopeia’s requirements. Starting from this remodeled bovine intestinal heparin, we report the preparation of a bovine intestinal low molecular weight heparin having the same structural properties and anti-factor IIa and anti-factor Xa activities of Enoxaparin. Moreover, this bovine intestinal heparin-derived “Enoxaparin” showed comparable platelet factor-4 binding affinity, suggesting that it should exhibit similarly low levels of heparin induced thrombocytopeneia, HIT.
Description
Journal of Medicinal Chemistry, 64, 2242-2253
Note : if this item contains full text it may be a preprint, author manuscript, or a Gold OA copy that permits redistribution with a license such as CC BY. The final version is available through the publisher’s platform.
Full Citation
Preparation of low molecular weight heparin from a remodeled bovine intestinal heparin, S. N. Baytas, S. S. Varghese, W. Jin, Y. Yu, P. He, M. Douaisi, F. Zhang, P. Brodfreur, K. Xia, J. S. Dordick, R. J. Linhardt, Journal of Medicinal Chemistry, 64, 2242-2253, 2021.
Publisher
Terms of Use
Journal
Volume
Issue
PubMed ID
DOI
ISSN
15204804
222623
EISSN